Skip to main content

Enzo's Q2 Revenues Improve 5 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Monday a 5 percent increase year over year in fiscal second-quarter revenues.

For the three months ended Jan. 31, total revenues rose to $25.0 million from $23.7 million driven by growth in the company's Clinical Labs segment and an increase in royalty and licensing revenues.

Clinical Labs revenues climbed to $14.1 million, a 15 percent increase year over year from $12.3 million, as Enzo further expanded its marketing efforts to reach more physicians and increase specimen volume, the New York-based firm said.

Meanwhile, royalty and licensing revenues rose 8 percent to $1.3 million from $1.2 million, but the Life Sciences segment experienced a 7 percent decrease in revenues to $9.5 million from $10.2 million, the result of continued softness in the academic market and "certain distributed products," Enzo said.

The company did not break out its R&D and SG&A spending, but said that total operating expenses contracted by $500,000 to a total of $15.4 million as R&D and legal expenses shrank. Enzo added, though, that it increased development efforts for its molecular tests and technology platform.

The firm's net loss for the quarter was $4.2 million, or $.11 per share, compared to $5.7 million, or $.15 per share, in Q2 2011.

Enzo finished the quarter with $18.6 million in cash, cash equivalents, and short-term investments.

Among the highlights mentioned its statement, Enzo noted the recent approval from New York to market GeneNews' Colon Sentry test to residents in the state.

In addition, later this month, Enzo expects to make a peer-reviewed presentation on its AmpiProbe technology platform at a conference in London. It said that it initially plans to have CE-IVD designation to market the AmpiProbe HCV test in the European Union as the first assay based on the platform. Enzo also plans to seek approval in New York to market the test as an LDT, it added.

Last week, the company announced a series of lawsuits against Abbott, Becton Dickinson, and Hologic alleging patent infringement, following a similar lawsuit in January against Roche, Life Technologies, and Gen-Probe.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.